InnoCare Pharma’s ICP-723 Joins China’s SPARK Project for Pediatric Solid Tumors

China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has announced plans to include Beijing InnoCare Pharma’s (HKG: 9969) ICP-723 orally disintegrating tablets in the “Support Anti-tumor drugs R&D for Kids (SPARK) project”. This initiative aims to develop ICP-723 for treating pediatric solid tumor patients with NTRK gene fusions.

ICP-723: A New Hope for Pediatric Patients
ICP-723 (zurletrectinib), a second-generation pan-TRK inhibitor, has been approved for clinical trials in children aged 2 to 12. It offers a promising new treatment option for pediatric patients with NTRK gene fusion-driven solid tumors.-Fineline Info & Tech